Catalyst Pharmaceuticals shares face Nasdaq suspension as company moves to delist after merger
CPRX•Nasdaq suspension and delisting plans
Catalyst Pharmaceuticals notified Nasdaq of its merger close, seeking removal of its common stock from the Nasdaq Capital Market.
- Nasdaq was asked to keep the trading halt in place through July 15, 2026; the stock is set to be suspended July 16, 2026.
- The company expects Nasdaq to file a Form 25 to delist and deregister the shares under Exchange Act Section 12(b).
- Following Form 25 effectiveness, Catalyst plans to file a Form 15 to terminate registration under Section 12(g), suspending reporting under Sections 13 and 15(d).
